KRAS Gene Analysis (Codons 12, 13, 61, 146)

A blood sample is taken through a needle from the arm, or a tissue sample may be obtained from a tumor through a biopsy procedure.

The test identifies mutations in codons 12, 13, 61, and 146 of the KRAS gene. These mutations are common in various cancers and can influence treatment options and prognosis.

If a KRAS mutation is identified, it can indicate that the tumor may not respond to certain targeted therapies, and alternative treatment options should be considered.

KRAS Gene Analysis is usually performed once, at the time of cancer diagnosis or before starting therapy, to inform treatment decisions.

Normal results would indicate no mutations in the analyzed codons of the KRAS gene. The presence of mutations would be considered abnormal.

There are no specific precautions. However, patients should follow the doctor's instructions and be prepared to discuss treatment options based on the results.

KRAS mutations are genetic changes and are not influenced by lifestyle or environmental factors.

In case of abnormal results, an oncologist should be consulted for proper diagnosis and treatment planning.

Codons 12, 13, 61, and 146 are regions in the KRAS gene where mutations are commonly found in cancers. These mutations are known to impact the protein function and influence how the cancer responds to treatment.

This analysis is not used as a predictive test for the likelihood of developing cancer; it is used to inform treatment decisions for patients who have already been diagnosed with cancer.

KRAS mutations are most commonly associated with colorectal cancer, lung cancer, and pancreatic cancer.

Yes, often the NRAS and BRAF genes are also tested along with KRAS as mutations in these genes can also have implications on treatment decisions.

No, KRAS mutations are genetic changes within the cells and are not affected by lifestyle or dietary changes.

Determining the genetic characteristics of a tumor is critical in cancer management. KRAS Gene Analysis, particularly at codons 12, 13, 61, and 146, provides invaluable information regarding the genetic makeup of the tumor. This information is pivotal in making informed decisions on treatment strategies. Consulting an oncologist with the results of this analysis is essential to understand and discuss the most effective treatment options available based on the tumor’s genetic profile.